Pre-Clinical Evaluation of a Novel Immunomodulator: a potential immunotherapy for coronaviral disease

Abstract

At present, no unifying animal study to quantify the effect of PI on innate immunity in animals has been reported. This study quantifies the effect of PI in mice and THP-1 cells using a multi-disciplinary approach employing flow cytometry to measure immune function and mass spectroscopy to identify metabolomic profiles of treated cells. For proof of principle, a case study was conducted to examine the potential benefit of administering PI to improve outcomes of a feline leukemia-positive cat that also contracted the effusive form of FIP. Our results indicate that quantifiable cellular and metabolic markers result from PI treatment and can be used to establish a platform measuring the efficacy of PI in modulating the innate immune system.